Biosensors   

Is Biosensors a good buy?

Hi Allright bro... is a yahoo link there.... for me...im not sure about this news...so...trying to check out with Bengster.... and he have given some comment on it.... look like some old news been recycle again...

 

Yes Novena33 and bengster. Saw that article in Yahoo finance. Was this paragraph-(taken from your article)

"A third drug-releasing stent will come onto the market in 2008, "which yielded similar or fewer major adverse cardiac events among patients," according to the editorial authored by Debabrata Mukherjee and David Moliterno of the University of Kentucky, Lexington."

refering to BIG???  Really BIG manage the results on 4th February in a positive manner

 

Results on 4th february 2008 after trading hours. HOPE the management can give a clearer more positive guidance this time.

 

To show AK support, I didn't sell all my BIG, I still keep some. Cheers for the best.

 

Hello bengster68, I am sure you are not the only believer of Biosensors.  There are many lizards who quietly share your believe and that includes me. 

Very much appreciate your kind sharing of info and thoughts.

 

The article is relating some previous news. Some say Cypher is better than Taxus while some say they are equivalent. BIG will report losses for Q3 but should report profit in Q4. I continue to stand by my earnings estimation of at least US$25m ending Mar 2008 and over US$100m for FY2009. I know im the odd one out  here but im confident of my earnings forecast for BIG.

 

Consider it beginning next yr, as it may make profit next half yr. Use your cash to buy others counter leow.

 

I will be collecting BIG soon after liquidating all my counters 2 weeks ago. Well, I escaped the meltdown at least. In fact I made a little last week by shorting several counters.

Support at 71-72 cents. I think I will get in slowly. Rushing into the mkt in these current volatile mkt will be risky. Slowly cherry pick, there are other counters quite tempting too. All at historic low now.

 

Hi Benster, what ur views on this article?

http://sg.news.yahoo.com/afp/20080130/tts-health-research-us-heart-972e412.html

 

Hi Younglady................... guess most of us....if not all of us have vest or common interest in this counter...is just the size that different....... dont think other thing ok.....

 

sleeping time

 

hey so quiet today again???? ahaha wei bengstar wat u doing??? u r the moderator of the biosensors forum. how many lots u holding on???? Mr beng

 

Johnson & Johnson (JNJ) reported a 9.5% rise in fourth-quarter net income as the pharmaceuticals company benefited from favorable foreign-exchange rates, strong consumer-products sales and a year-earlier charge. The firm saw continued declines in its drug-coated stent sales. New Brunswick, N.J.-based Johnson & Johnson posted net income of $2.37 billion, or 82 cents a share, up from $2.17 billion, or 74 cents a share, a year earlier. The latest results include a $441 million write-down on heart drug Natrecor that reflects revised estimates of future cash flow due to a recent decline in sales trends and a tax gain of $267 million associated with international restructuring. Prior-year results include $217 million in charges related to the acquisition of Pfizer Inc. (PFE)'s consumer-products division. Excluding items, earnings rose to 88 cents a share from 81 cents a share. Revenue rose 17% to $15.96 billion, with five percentage points coming from the weaker dollar. The mean estimates of analysts polled by Thomson Financial were for earnings of 86 cents a share on $15.4 billion in revenue. Shares of Johnson & Johnson fell to $64.50 in recent premarket activity after closing Friday at $66.29. Domestic sales increased 9.1% to $8.23 billion. International sales jumped 26% to $7.73 billion, with 11 percentage points coming from currency fluctuations. Revenue in the company's medical-devices business rose 11%, largely on currency impacts, as sales of the Cypher drug-coated stent fell. J&J didn't give precise figures. Stents are tiny mesh devices used to prop open heart arteries, and coated stents use medication to combat re-narrowing. Johnson & Johnson's drug-coated stent sales have been declining since 2006 amid reports that the devices may carry a higher risk of blood-clot development than those uncoated in certain medications. Johnson & Johnson's consumer-product division saw sales rise 49% amid the Pfizer deal, reflecting strong performance of Listerine antiseptic mouthrinse and the launch of whitening products; Baby and Kids Care products; its skin-care lines; and Splenda sweetener, among other products. Meanwhile, sales in the pharmaceuticals unit rose 7.5%, largely benefiting from strong sales for Risperdal, its antipsychotic medication. The drug is due to lose its market exclusivity in June, clearing the way for cheaper, generic versions. The segment's growth was hurt by lower sales of Procrit, a product for the treatment of anemia, due to a decline in the market related to labeling changes made during the year and a decision memorandum issued by the Centers for Medicare and Medicaid Services under its national coverage analysis process. "Despite challenges in certain markets, our broad base of businesses allowed us to achieve solid results in 2007, building on our foundation of long-term profitable growth," Chairman and Chief Executive William C. Weldon said. "It was a year of significant progress in our pipeline; the successful integration of Pfizer Consumer Healthcare; and the creation of new organizational structures focused on future growth." Big pharmaceutical companies such as Johnson & Johnson face a mounting crisis as their pipelines shorten and their top-selling drugs face generic competition as their patent protections expire. Generic competition is expected to wipe $67 billion from top pharmaceutical companies' annual U.S. sales between 2007 and 2012 as more than three dozen drugs lose patent protection. To help cope, Johnson & Johnson in November said it would reshuffle management and reorganize some units to improve its focus on existing businesses while exploring new market opportunities. That followed the company's July announcement that it would cut 3% to 4% of its work force to adjust to the downturn in sales for key products.

 

I was so "tui" (frust), because I had placed my shorting order on last Friday night @1.10 thinking I will be ahead of the queue.

Then on Monday, it really hit 1.10 exactly, but my order was not done because of orders ahead of me.
It then went down all the way from 1.10 till .775 today.


Next time, I must learn this lesson well and place my order one or two clicks less....

 

Using Jap candlesticks, the chart had turn bearish on 22nd jan, when BIG closed at 0.90 cents, forming a 'bearish engulfing pattern'.

This was followed by a gap down the following day, and breaking the minor support at 0.895.

The question now is - where will be the next strong support ? There is a trend line drawn from 17th aug low (0.585) joining 20th nov low (0.66), and joining joining 18th dec low at 0.69 - extrapolating this line bring us forward to a level at about 0.73 cents.

Today's low was 0.735, forming a nice 'hammer', but unfortunately, without the hugh vol, necessary to 'hammer out' a low.

Let's see how tomorrow's price action will be !.

 

TA charts look bearish. Acc/Dist heading southwards. Price bars are trailing the lower bollinger band too.

 

it is me lah , i buy at .77 :))))

 

what a close.....  BB is in control of the price.......

 

Im not quite at 5,000 lots yet. 5,000 lots is my target i hope i will be holding when BIG kena takeover. This is a volatile stock and I will only buy when its cheap to lower my risk. But the cheap can get cheaper tomorrow. As long as you are happy of your purchase and comfortable, its ok.  

 

Suddenly kanna pump to 0.77 with a single lot.
Funny business happening.
But dunno is it to trick players into buying because of 0.765 resistance is breeched.
Bros beware. If tomorrow DJ not good it will use excuse to pump down.